Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1905 in Severe Uncontrolled Asthma
NCT05593250Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1905 in asthma, sponsored by Hengrui Therapeutics. Started Jan 2023; status: completed.
02
Drugs
SHR-1905
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05593250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05593250.